35 results on '"Fetsch, Patricia"'
Search Results
2. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
- Author
-
Cole CB, Morelli MP, Fantini M, Miettinen M, Fetsch P, Peer C, Figg WD, Yin T, Houston N, McCoy A, Lipkowitz S, Zimmer A, Lee JM, Pavelova M, Villanueva EN, Trewhitt K, Solarz BB, Fergusson M, Mavroukakis SA, Zaki A, Tsang KY, Arlen PM, and Annunziata CM
- Subjects
- Adult, Female, Humans, Disease Progression, Febrile Neutropenia chemically induced, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Colorectal Neoplasms drug therapy, Pancreatic Neoplasms drug therapy
- Abstract
Background: NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by its target cells. Here, we present outcomes from a phase I trial of NEO-201 in patients with advanced solid tumors that have not responded to standard treatments., Methods: This was a single site, open label 3 + 3 dose escalation clinical trial. NEO-201 was administered intravenously every two weeks in a 28-day cycle at dose level (DL) 1 (1 mg/kg), DL 1.5 (1.5 mg/kg) and DL 2 (2 mg/kg) until dose limiting toxicity (DLT), disease progression, or patient withdrawal. Disease evaluations were conducted after every 2 cycles. The primary objective was to assess the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of NEO-201. The secondary objective was to assess the antitumor activity by RECIST v1.1. The exploratory objectives assessed pharmacokinetics and the effect of NEO-201 administration on immunologic parameters and their impact on clinical response., Results: Seventeen patients (11 colorectal, 4 pancreatic and 2 breast cancers) were enrolled; 2 patients withdrew after the first dose and were not evaluable for DLT. Twelve of the 15 patients evaluable for safety discontinued due to disease progression and 3 patients discontinued due to DLT (grade 4 febrile neutropenia [1 patient] and prolonged neutropenia [1 patient] at DL 2, and grade 3 prolonged (> 72 h) febrile neutropenia [1 patient] at DL 1.5). A total of 69 doses of NEO-201 were administered (range 1-15, median 4). Common (> 10%) grade 3/4 toxicities occurred as follows: neutropenia (26/69 doses, 17/17 patients), white blood cell decrease (16/69 doses, 12/17 patients), lymphocyte decrease (8/69 doses, 6/17 patients). Thirteen patients were evaluable for disease response; the best response was stable disease (SD) in 4 patients with colorectal cancer. Analysis of soluble factors in serum revealed that a high level of soluble MICA at baseline was correlated with a downregulation of NK cell activation markers and progressive disease. Unexpectedly, flow cytometry showed that NEO-201 also binds to circulating regulatory T cells and reduction of the quantities of these cells was observed especially in patients with SD., Conclusions: NEO-201 was safe and well tolerated at the MTD of 1.5 mg/kg, with neutropenia being the most common adverse event. Furthermore, a reduction in the percentage of regulatory T cells following NEO-201 treatment supports our ongoing phase II clinical trial evaluating the efficiency of the combination of NEO-201 with the immune checkpoint inhibitor pembrolizumab in adults with treatment-resistant solid tumors., Trial Registration: NCT03476681 . Registered 03/26/2018., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
3. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
- Author
-
Qu S, Fetsch P, Thomas A, Pommier Y, Schrump DS, Miettinen MM, and Chen H
- Subjects
- Basic Helix-Loop-Helix Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Humans, Nuclear Proteins, Octamer Transcription Factors, Synaptophysin, YAP-Signaling Proteins, Lung Neoplasms genetics, Neuroendocrine Tumors genetics, Small Cell Lung Carcinoma genetics
- Abstract
Introduction: A new molecular subtype classification was recently proposed for SCLC. It is necessary to validate it in primary SCLC tumors by immunohistochemical (IHC) staining and define its clinical relevance., Methods: We used IHC to assess four subtype markers (ASCL1, NEUROD1, POU2F3, and YAP1) in 194 cores from 146 primary SCLC tumors. The profiles of tumor-associated CD3
+ and CD8+ T-cells, MYC paralogs, SLFN11, and SYP were compared among different subtypes. Validation was performed using publicly available RNA sequencing data of SCLC., Results: ASCL1, NEUROD1, POU2F3, and YAP1 were the dominant molecular subtypes in 78.2%, 5.6%, 7%, and 2.8% of the tumors, respectively; 6.3% of the tumors were negative for all four subtype markers. Notably, three cases were uniquely positive for YAP1. Substantial intratumoral heterogeneity was observed, with 17.6% and 2.8% of the tumors being positive for two and three subtype markers, respectively. The non-ASCL1/NEUROD1 tumors had more CD8+ T-cells and manifested more frequently an "inflamed" immunophenotype. L-MYC and MYC were more often associated with ASCL1/NEUROD1 subtypes and non-ASCL1/NEUROD1 subtypes, respectively. SLFN11 expression was absent in 40% of the tumors, especially those negative for the four subtype markers. SYP was often expressed in the ASCL1 and NEUROD1 subtypes and was associated with less tumor-associated CD8+ T-cells and a "desert" immunophenotype., Conclusions: We validated the new molecular subtype classification in primary SCLC tumors by IHC and identified several intriguing associations between subtypes and therapeutic markers. The new subtype classification may potentially assist treatment decisions in SCLC., (Published by Elsevier Inc.)- Published
- 2022
- Full Text
- View/download PDF
4. Neutrophil and Eosinophil Extracellular Traps in Hodgkin Lymphoma.
- Author
-
Francischetti IMB, Alejo JC, Sivanandham R, Davies-Hill T, Fetsch P, Pandrea I, Jaffe ES, and Pittaluga S
- Abstract
Classic Hodgkin lymphoma (cHL), nodular sclerosis (NS) subtype, is characterized by the presence of Hodgkin/Reed-Sternberg (HRS) cells in an inflammatory background containing neutrophils and/or eosinophils. Both types of granulocytes release extracellular traps (ETs), web-like DNA structures decorated with histones, enzymes, and coagulation factors that promote inflammation, thrombosis, and tumor growth. We investigated whether ETs from neutrophils (NETs) or eosinophils (EETs) are detected in cHL, and evaluated their association with fibrosis. We also studied expression of protease-activated receptor-2 (PAR-2) and phospho-extracellular signal-related kinase (p-ERK), potential targets/effectors of ETs-associated elastase, in HRS cells. Expression of tissue factor (TF) was evaluated, given the procoagulant properties of ETs. We analyzed 32 HL cases, subclassified as 12 NS, 5 mixed-cellularity, 5 lymphocyte-rich, 1 lymphocyte-depleted, 4 nodular lymphocyte-predominant HL (NLPHL), and 5 reactive nodes. Notably, a majority of NS cHL cases exhibited NET formation by immunohistochemistry for citrullinated histones, with 1 case revealing abundant EETs. All other cHL subtypes as well as NLPHL were negative. Immunofluorescence microscopy confirmed NETs with filamentous/delobulated morphology. Moreover, ETs formation correlates with concurrent fibrosis ( r = 0.7999; 95% CI, 0.6192-0.9002; P ≤ 0.0001). Results also showed that HRS cells in NS cHL expressed PAR-2 with nuclear p-ERK staining, indicating a neoplastic or inflammatory phenotype. Remarkably, TF was consistently detected in the endothelium of NS cHL cases compared with other subtypes, in keeping with a procoagulant status. A picture emerges whereby the release of ETs and resultant immunothrombosis contribute to the inflammatory tumor microenvironment of NS cHL. This is the first description of NETs in cHL., (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)
- Published
- 2021
- Full Text
- View/download PDF
5. Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors.
- Author
-
Mamilla D, Manukyan I, Fetsch PA, Pacak K, and Miettinen M
- Subjects
- Adult, Aged, Cauda Equina pathology, Duodenal Neoplasms diagnosis, Female, Humans, Immunohistochemistry, Male, Middle Aged, Peripheral Nervous System Neoplasms diagnosis, Biomarkers, Tumor analysis, Carcinoma, Neuroendocrine diagnosis, Paraganglioma diagnosis
- Abstract
Distinction of paraganglioma (PGL) from epithelial neuroendocrine tumors (NETs) can be difficult as they can mimic each other by nested architecture and expression of neuroendocrine markers. In this study, we examined differential diagnostic markers in 262 PGLs (142 adrenal pheochromocytomas and 120 extra-adrenal PGLs), 9 duodenal gangliocytic PGLs and 3 cauda equina PGLs, and 286 NETs (81 GI, 78 pancreatic, 42 thoracic, 37 medullary thyroid carcinomas, and 48 high-grade NETs including 32 small cell carcinomas of lung). While keratin expression was nearly uniform in NETs with the exception of few tumors, extensive keratin expression was seen in only one PGL (<1%) and focal expression in 5% PGLs. GATA3 was present in >90% of PGLs but only in 2% of NETs, usually focally. Tyrosine hydroxylase (TH) was expressed in >90% of adrenal, abdominal, and thoracic PGLs but only in 37% of head and neck PGLs, reflecting their variable catecholamine synthesis. Focal or occasional extensive TH-expression was detected in 10% of NETs. CDX2 was a helpful discriminator seen in 28% of pancreatic and most GI NETs but in no PGLs. SOX10 detected sustentacular cells in 85% of PGLs and 7% of NETs, whereas GFAP detected sustentacular cells mainly in PGLs of neck and was absent in NETs. Duodenal gangliocytic PGLs (n = 9) and all cauda equina PGLs (n = 3) expressed keratins, lacked GATA3, showed no or minimal TH expression as some NETs, and contained SOX10 and S100 protein-positive spindle cells negative for GFAP. Ganglion-like epithelioid cells were keratin-positive and negative for TH and SOX10 differing from true ganglion cells. We conclude that duodenal gangliocytic and cauda equina PGLs have a NET-like immunoprofile and differ from ordinary PGLs. NETs can be distinguished from PGLs by their expression of keratins and general lack of GATA3, TH, and GFAP-positive sustentacular cells, and sometimes by expression of CDX2 or TTF1., (Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
6. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
- Author
-
Rathkey D, Khanal M, Murai J, Zhang J, Sengupta M, Jiang Q, Morrow B, Evans CN, Chari R, Fetsch P, Chung HJ, Xi L, Roth M, Filie A, Raffeld M, Thomas A, Pommier Y, and Hassan R
- Subjects
- Cell Line, Tumor, Guanine analogs & derivatives, Humans, O(6)-Methylguanine-DNA Methyltransferase, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, Temozolomide pharmacology, Tumor Suppressor Proteins genetics, Ubiquitin Thiolesterase genetics, Lung Neoplasms, Mesothelioma drug therapy, Mesothelioma genetics
- Abstract
Introduction: BRCA1-associated protein-1 (BAP1), a nuclear deubiquitinase thought to be involved in DNA double-strand break repair, is frequently mutated in mesothelioma. Because poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPIs) induce synthetic lethality in BRCA1/2 mutant cancers, we evaluated whether BAP1 inactivating mutations confer sensitivity to PARPIs in mesothelioma and if combination therapy with temozolomide (TMZ) would be beneficial., Methods: A total of 10 patient-derived mesothelioma cell lines were generated and characterized for BAP1 mutation status, protein expression, nuclear localization, and sensitivity to the PARPIs, olaparib, and talazoparib, alone or in combination with TMZ. BAP1 deubiquitinase (DUB) activity was evaluated by ubiquitin with 7-amido-4-methylcoumarin assay. BAP1 knockout mesothelioma cell lines were generated by CRISPR-Cas9. Because Schlafen 11 (SLFN11) and O
6 -methylguanine-DNA methyltransferase also drive response to TMZ and PARPIs, we tested their expression and relationship with drug response., Results: BAP1 mutations or copy-number alterations, or both were present in all 10 cell lines. Nonetheless, four cell lines exhibited intact DUB activity and two had nuclear BAP1 localization. Half maximal-inhibitory concentrations of olaparib and talazoparib ranged from 4.8 μM to greater than 50 μM and 0.039 μM to greater than 5 μM, respectively, classifying them into sensitive (two) or resistant (seven) cells, independent of their BAP1 status. Cell lines with BAP1 knockout resulted in the loss of BAP1 DUB activity but did not increase sensitivity to talazoparib. Response to PARPI tended to be associated with high SLFN11 expression, and combination with temozolomide increased sensitivity of cells with low or no MGMT expression., Conclusions: BAP1 status does not determine sensitivity to PARPIs in patient-derived mesothelioma cell lines. Combination of PARPI with TMZ may be beneficial for patients whose tumors have high SLFN11 and low or no MGMT expression., (Published by Elsevier Inc.)- Published
- 2020
- Full Text
- View/download PDF
7. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
- Author
-
Pemov A, Hansen NF, Sindiri S, Patidar R, Higham CS, Dombi E, Miettinen MM, Fetsch P, Brems H, Chandrasekharappa SC, Jones K, Zhu B, Wei JS, Mullikin JC, Wallace MR, Khan J, Legius E, Widemann BC, and Stewart DR
- Subjects
- Cyclin-Dependent Kinase Inhibitor p15 genetics, Cyclin-Dependent Kinase Inhibitor p16 genetics, Humans, Mutation genetics, Transcription Factors, Nerve Sheath Neoplasms, Neurofibroma, Neurofibroma, Plexiform, Neurofibromatosis 1 genetics, Neurofibrosarcoma
- Abstract
Background: Neurofibromatosis type 1 (NF1) is a tumor-predisposition disorder caused by germline mutations in NF1. NF1 patients have an 8-16% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST), a highly aggressive soft-tissue sarcoma, often arising from preexisting benign plexiform neurofibromas (PNs) and atypical neurofibromas (ANFs). ANFs are distinct from both PN and MPNST, representing an intermediate step in malignant transformation., Methods: In the first comprehensive genomic analysis of ANF originating from multiple patients, we performed tumor/normal whole-exome sequencing (WES) of 16 ANFs. In addition, we conducted WES of 3 MPNSTs, copy-number meta-analysis of 26 ANFs and 28 MPNSTs, and whole transcriptome sequencing analysis of 5 ANFs and 5 MPNSTs., Results: We identified a low number of mutations (median 1, range 0-5) in the exomes of ANFs (only NF1 somatic mutations were recurrent), and frequent deletions of CDKN2A/B (69%) and SMARCA2 (42%). We determined that polycomb repressor complex 2 (PRC2) genes EED and SUZ12 were frequently mutated, deleted, or downregulated in MPNSTs but not in ANFs. Our pilot gene expression study revealed upregulated NRAS, MDM2, CCND1/2/3, and CDK4/6 in ANFs and MPNSTs, and overexpression of EZH2 in MPNSTs only., Conclusions: The PN-ANF transition is primarily driven by the deletion of CDKN2A/B. Further progression from ANF to MPNST likely involves broad chromosomal rearrangements and frequent inactivation of the PRC2 genes, loss of the DNA repair genes, and copy-number increase of signal transduction and cell-cycle and pluripotency self-renewal genes., (Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2019.)
- Published
- 2019
- Full Text
- View/download PDF
8. Immunophenotypic Characterization of Canine Splenic Follicular-Derived B-Cell Lymphoma.
- Author
-
Stein L, Bacmeister C, Ylaya K, Fetsch P, Wang Z, Hewitt SM, and Kiupel M
- Subjects
- Animals, Antigens, Differentiation, T-Lymphocyte immunology, Dog Diseases immunology, Dogs, Lymphoma, B-Cell immunology, Lymphoma, B-Cell pathology, Lymphoma, B-Cell, Marginal Zone immunology, Lymphoma, B-Cell, Marginal Zone pathology, Lymphoma, B-Cell, Marginal Zone veterinary, Lymphoma, Follicular immunology, Lymphoma, Follicular pathology, Lymphoma, Mantle-Cell immunology, Lymphoma, Mantle-Cell pathology, Lymphoma, Mantle-Cell veterinary, Retrospective Studies, Spleen immunology, Spleen pathology, Splenic Neoplasms immunology, Splenic Neoplasms pathology, Dog Diseases pathology, Immunophenotyping veterinary, Lymphoma, B-Cell veterinary, Lymphoma, Follicular veterinary, Splenic Neoplasms veterinary
- Abstract
Marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) belong to a subgroup of indolent B-cell lymphomas most commonly reported in the canine spleen. The goal of this study was to characterize the immunophenotype of splenic MZL and MCL in comparison to their human counterparts. Ten MCLs and 28 MZLs were selected based on morphology. A tissue microarray was generated, and expression of CD3, CD5, CD10, CD45, CD20, CD79a, Pax-5, Bcl-2, Bcl-6, cyclin D1, cyclin D3, MCL-1, MUM-1, and Sox-11 was evaluated. Neoplastic cells in all MCLs and MZLs were positive for CD5, CD20, CD45, CD79a, and BCL2 and negative for CD3, CD10, Bcl-6, cyclin D1, and cyclin D3. Positive labeling for Pax-5 was detected in 8 of 10 MCLs and 26 of 28 MZLs. Positive labeling for MUM-1 was detected in 3 of 10 MCLs, and 27 of 28 MZLs were positive for MUM-1. No MCLs but 8 of 24 MZLs were positive for MCL-1. Canine splenic MZL and MCL have a similar immunophenotype as their human counterparts. However, human splenic MCL overexpresses cyclin D1 due to a translocation. A similar genetic alteration has not been reported in dogs. In addition, in contrast to human MZL, canine splenic MZL generally expresses CD5. Following identification of B vs T cells with CD20 and CD3, a panel composed of BCL-2, Bcl-6, MUM-1, and MCL-1 combined with the histomorphological pattern can be used to accurately diagnose MZL and MCL in dogs. Expression of Bcl-2 and lack of MCL-1 expression in MCL may suggest a therapeutic benefit of BCL-2 inhibitors in canine MCL.
- Published
- 2019
- Full Text
- View/download PDF
9. Re-evaluating TTF-1 immunohistochemistry in diffuse gliomas: Expression is clone-dependent and associated with tumor location.
- Author
-
Pratt D, Afsar N, Allgauer M, Fetsch P, Palisoc M, Pittaluga S, and Quezado M
- Subjects
- Adult, Aged, Female, Humans, Immunohistochemistry methods, Male, Middle Aged, Young Adult, Antibodies, Monoclonal, Biomarkers, Tumor analysis, Brain Neoplasms diagnosis, DNA-Binding Proteins analysis, Glioma diagnosis, Transcription Factors analysis
- Abstract
TTF-1 is widely used as a marker in routine surgical pathology in the work-up of malignancy. Aberrant expression of TTF-1 in extrapulmonary and extrathyroidal malignancies is a frequently reported phenomenon. In addition to the recently characterized pituicyte-derived tumors of the sella, immunoreactivity has been reported in diffuse gliomas with the SPT24 clone. Here, we sought to evaluate TTF-1 expression with three commercially available clones in a large series of gliomas. Expression was compared across the newly defined diagnostic entities in the 2016 WHO Classification of CNS Tumors. Using tissue microarrays (TMA), 212 diffuse gliomas (WHO grades II - IV) were systematically evaluated with TTF-1 immunohistochemistry using three clones: SPT24, 8G7G3/1, and SP141, and results correlated with clinicopathologic features. 14 high-grade diffuse gliomas demonstrated nuclear staining with the SP141 and SPT24 clones. Two tumors showed weak positivity with the 8G7G3/1 clone. All tumors were high grade by histology (WHO grades III and IV). 86% (12/14) of TTF-1-positive gliomas involved the frontal lobes at diagnosis. No relationship with IDH R132H, ATRX, p53, H3K27M, or EGFR immunohistochemistry was identified. TTF-1 expression in gliomas was not independently prognostic of overall survival. TTF-1 expression in diffuse gliomas is a rare but potentially misleading occurrence. In our cohort, staining occurred with both the SPT24 and SP141 clones at equal intensity and frequency. Clustering of TTF-1-positive tumors in the frontal lobe(s) suggests lineage-specific expression. Due to clone-specific expression in diffuse gliomas, caution must be exercised in the work-up of intracranial tumors with TTF-1. .
- Published
- 2017
- Full Text
- View/download PDF
10. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.
- Author
-
Pratt D, Pittaluga S, Palisoc M, Fetsch P, Xi L, Raffeld M, Gilbert MR, and Quezado M
- Subjects
- Adolescent, Adult, Aged, Antigens, CD metabolism, Child, Child, Preschool, Cohort Studies, Databases, Factual statistics & numerical data, Female, Glial Fibrillary Acidic Protein metabolism, Humans, Isocitrate Dehydrogenase genetics, Male, Middle Aged, Mutation genetics, Tissue Array Analysis, Young Adult, Brain Neoplasms genetics, Brain Neoplasms metabolism, Brain Neoplasms pathology, CD27 Ligand metabolism, Glioblastoma genetics, Glioblastoma metabolism, Glioblastoma pathology, Gliosarcoma genetics, Gliosarcoma metabolism, Gliosarcoma pathology
- Abstract
Glioblastoma is an aggressive, often recalcitrant disease. In the majority of cases, prognosis is dismal and current therapies only moderately prolong survival. Immunotherapy is increasingly being recognized as an effective treatment modality. CD70 is a transmembrane protein that shows restricted expression in tissue but has been described in various malignancies. Therapeutic targeting of CD70 has demonstrated antitumor efficacy and is in clinical trials. Here, we sought to characterize CD70 expression in a large cohort of gliomas (n = 205) using tissue microarrays. We identified a subset of tumors (n = 18, 8.8% of high-grade gliomas) exhibiting moderate-to-strong immunoreactivity that enriched for the IDH-wild-type glioblastoma variants gliosarcoma (n = 10) and the newly described epithelioid glioblastoma (n = 4). CD70 expression was associated with prolonged survival in gliosarcoma. Analysis of TCGA datasets showed significantly increased CD70 expression in mesenchymal tumors and prolonged survival in recurrent non-G-CIMP high-expressing tumors. In CD70+ gliomas, there was a significant increase in CD68/CD163/HLA-DR+ tumor-associated macrophages, but not CD27+ TIL. These results confirm prior in vitro studies and demonstrate expression in a clinical cohort. The absence of CD70 expression in the post-treatment setting may portend more clinically aggressive disease in gliosarcoma. However, larger-scale studies will be needed to characterize and validate this relationship., (2017 American Association of Neuropathologists, Inc. This work is written by US Government employees and is in the public domain in the US.)
- Published
- 2017
- Full Text
- View/download PDF
11. High-Throughput Microdissection for Next-Generation Sequencing.
- Author
-
Rosenberg AZ, Armani MD, Fetsch PA, Xi L, Pham TT, Raffeld M, Chen Y, O'Flaherty N, Stussman R, Blackler AR, Du Q, Hanson JC, Roth MJ, Filie AC, Roh MH, Emmert-Buck MR, Hipp JD, and Tangrea MA
- Subjects
- Animals, Cell Nucleus metabolism, Epithelium metabolism, Humans, Mice, NIH 3T3 Cells, Staining and Labeling, High-Throughput Nucleotide Sequencing methods, Microdissection methods
- Abstract
Precision medicine promises to enhance patient treatment through the use of emerging molecular technologies, including genomics, transcriptomics, and proteomics. However, current tools in surgical pathology lack the capability to efficiently isolate specific cell populations in complex tissues/tumors, which can confound molecular results. Expression microdissection (xMD) is an immuno-based cell/subcellular isolation tool that procures targets of interest from a cytological or histological specimen. In this study, we demonstrate the accuracy and precision of xMD by rapidly isolating immunostained targets, including cytokeratin AE1/AE3, p53, and estrogen receptor (ER) positive cells and nuclei from tissue sections. Other targets procured included green fluorescent protein (GFP) expressing fibroblasts, in situ hybridization positive Epstein-Barr virus nuclei, and silver stained fungi. In order to assess the effect on molecular data, xMD was utilized to isolate specific targets from a mixed population of cells where the targets constituted only 5% of the sample. Target enrichment from this admixed cell population prior to next-generation sequencing (NGS) produced a minimum 13-fold increase in mutation allele frequency detection. These data suggest a role for xMD in a wide range of molecular pathology studies, as well as in the clinical workflow for samples where tumor cell enrichment is needed, or for those with a relative paucity of target cells.
- Published
- 2016
- Full Text
- View/download PDF
12. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
- Author
-
Rao M, Atay SM, Shukla V, Hong Y, Upham T, Ripley RT, Hong JA, Zhang M, Reardon E, Fetsch P, Miettinen M, Li X, Peer CJ, Sissung T, Figg WD, De Rienzo A, Bueno R, and Schrump DS
- Subjects
- Animals, Apoptosis drug effects, Biomarkers, Tumor genetics, Cell Proliferation drug effects, Cellular Senescence drug effects, Female, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms genetics, Lung Neoplasms pathology, Mesothelioma genetics, Mesothelioma pathology, Mesothelioma, Malignant, Mice, Middle Aged, Pleural Neoplasms genetics, Pleural Neoplasms pathology, Plicamycin administration & dosage, RNA, Messenger biosynthesis, Sp1 Transcription Factor antagonists & inhibitors, Sp1 Transcription Factor genetics, Tumor Suppressor Protein p53 genetics, Xenograft Model Antitumor Assays, Biomarkers, Tumor biosynthesis, Lung Neoplasms drug therapy, Mesothelioma drug therapy, Pleural Neoplasms drug therapy, Sp1 Transcription Factor biosynthesis, Tumor Suppressor Protein p53 biosynthesis
- Abstract
Purpose: Specificity protein 1 (SP1) is an oncogenic transcription factor overexpressed in various human malignancies. This study sought to examine SP1 expression in malignant pleural mesotheliomas (MPM) and ascertain the potential efficacy of targeting SP1 in these neoplasms., Experimental Design: qRT-PCR, immunoblotting, and immunohistochemical techniques were used to evaluate SP1 expression in cultured MPM cells and MPM specimens and normal mesothelial cells/pleura. MTS, chemotaxis, soft agar, β-galactosidase, and Apo-BrdUrd techniques were used to assess proliferation, migration, clonogenicity, senescence, and apoptosis in MPM cells following SP1 knockdown, p53 overexpression, or mithramycin treatment. Murine subcutaneous and intraperitoneal xenograft models were used to examine effects of mithramycin on MPM growth in vivo. Microarray, qRT-PCR, immunoblotting, and chromatin immunoprecipitation techniques were used to examine gene expression profiles mediated by mithramycin and combined SP1 knockdown/p53 overexpression and correlate these changes with SP1 and p53 levels within target gene promoters., Results: MPM cells and tumors exhibited higher SP1 mRNA and protein levels relative to control cells/tissues. SP1 knockdown significantly inhibited proliferation, migration, and clonogenicity of MPM cells. Mithramycin depleted SP1 and activated p53, dramatically inhibiting proliferation and clonogenicity of MPM cells. Intraperitoneal mithramycin significantly inhibited growth of subcutaneous MPM xenografts and completely eradicated mesothelioma carcinomatosis in 75% of mice. Mithramycin modulated genes mediating oncogene signaling, cell-cycle regulation, senescence, and apoptosis in vitro and in vivo. The growth-inhibitory effects of mithramycin in MPM cells were recapitulated by combined SP1 knockdown/p53 overexpression., Conclusions: These findings provide preclinical rationale for phase II evaluation of mithramycin in patients with mesothelioma., (©2015 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
13. Human-Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1).
- Author
-
Pluchino KM, Hall MD, Moen JK, Chufan EE, Fetsch PA, Shukla S, Gill DR, Hyde SC, Xia D, Ambudkar SV, and Gottesman MM
- Subjects
- ATP Binding Cassette Transporter, Subfamily B antagonists & inhibitors, ATP Binding Cassette Transporter, Subfamily B chemistry, ATP Binding Cassette Transporter, Subfamily B genetics, Animals, Antineoplastic Agents pharmacology, Biological Transport drug effects, Cell Line, Cell Line, Transformed, Drug Resistance, Neoplasm, HeLa Cells, Humans, Kinetics, Lepidoptera, Membrane Transport Modulators pharmacology, Mice, Peptide Fragments antagonists & inhibitors, Peptide Fragments chemistry, Peptide Fragments genetics, Peptide Fragments metabolism, Protein Structure, Tertiary, Recombinant Fusion Proteins chemistry, Recombinant Fusion Proteins genetics, Recombinant Proteins chemistry, Recombinant Proteins genetics, ATP Binding Cassette Transporter, Subfamily B metabolism, Fluorescent Dyes metabolism, Models, Molecular, Recombinant Fusion Proteins metabolism, Recombinant Proteins metabolism
- Abstract
The efflux transporter P-glycoprotein (P-gp) plays a vital role in the transport of molecules across cell membranes and has been shown to interact with a panoply of functionally and structurally unrelated compounds. How human P-gp interacts with this large number of drugs has not been well understood, although structural flexibility has been implicated. To gain insight into this transporter's broad substrate specificity and to assess its ability to accommodate a variety of molecular and structural changes, we generated human-mouse P-gp chimeras by the exchange of homologous transmembrane and nucleotide-binding domains. High-level expression of these chimeras by BacMam- and baculovirus-mediated transduction in mammalian (HeLa) and insect cells, respectively, was achieved. There were no detectable differences between wild-type and chimeric P-gp in terms of cell surface expression, ability to efflux the P-gp substrates rhodamine 123, calcein-AM, and JC-1, or to be inhibited by the substrate cyclosporine A and the inhibitors tariquidar and elacridar. Additionally, expression of chimeric P-gp was able to confer a paclitaxel-resistant phenotype to HeLa cells characteristic of P-gp-mediated drug resistance. P-gp ATPase assays and photo-cross-linking with [(125)I]iodoarylazidoprazosin confirmed that transport and biochemical properties of P-gp chimeras were similar to those of wild-type P-gp, although differences in drug binding were detected when human and mouse transmembrane domains were combined. Overall, chimeras with one or two mouse P-gp domains were deemed functionally equivalent to human wild-type P-gp, demonstrating the ability of human P-gp to tolerate major structural changes.
- Published
- 2016
- Full Text
- View/download PDF
14. Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules.
- Author
-
Valencia JC, Steagall WK, Zhang Y, Fetsch P, Abati A, Tsukada K, Billings E, Hearing VJ, Yu ZX, Pacheco-Rodriguez G, and Moss J
- Subjects
- Adult, Biopsy, Bronchoscopy, Cells, Cultured, Diagnosis, Differential, Female, Humans, Immunohistochemistry, Lung pathology, Lung Neoplasms immunology, Lymphangioleiomyomatosis immunology, Melanoma-Specific Antigens immunology, Middle Aged, Sensitivity and Specificity, Solitary Pulmonary Nodule immunology, gp100 Melanoma Antigen immunology, Antibodies, Anti-Idiotypic immunology, Lung Neoplasms diagnosis, Lung Neoplasms pathology, Lymphangioleiomyomatosis diagnosis, Lymphangioleiomyomatosis pathology, Solitary Pulmonary Nodule diagnosis, Solitary Pulmonary Nodule pathology
- Abstract
Background: Lymphangioleiomyomatosis (LAM) is characterized by the proliferation in the lung, axial lymphatics (eg, lymphangioleiomyomas), and kidney (eg, angiomyolipomas) of abnormal smooth muscle-like LAM cells, which express melanoma antigens such as Pmel17/gp100 and have dysfunctional tumor suppressor tuberous sclerosis complex (TSC) genes TSC2 or TSC1. Histopathologic diagnosis of LAM in lung specimens is based on identification of the Pmel17 protein with the monoclonal antibody HMB-45., Methods: We compared the sensitivity of HMB-45 to that of antipeptide antibody αPEP13h, which reacts with a C-terminal peptide of Pmel17. LAM lung nodules were laser-capture microdissected to identify proteins by Western blotting., Results: HMB-45 recognized approximately 25% of LAM cells within the LAM lung nodules, whereas αPEP13h identified > 82% of LAM cells within these structures in approximately 90% of patients. Whereas HMB-45 reacted with epithelioid but not with spindle-shaped LAM cells, αPEP13h identified both spindle-shaped and epithelioid LAM cells, providing greater sensitivity for detection of all types of LAM cells. HMB-45 recognized Pmel17 in premelanosomal organelles; αPEP13h recognized proteins in the cytoplasm as well as in premelanosomal organelles. Both antibodies recognized a Pmel17 variant of approximately 50 kDa., Conclusions: Based on its sensitivity and specificity, αPEP13h may be useful in the diagnosis of LAM and more sensitive than HMB-45.
- Published
- 2015
- Full Text
- View/download PDF
15. Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration.
- Author
-
Bartlett EK, Fetsch PA, Filie AC, Abati A, Steinberg SM, Wunderlich JR, White DE, Stephens DJ, Marincola FM, Rosenberg SA, and Kammula US
- Subjects
- CD4-Positive T-Lymphocytes metabolism, CD4-Positive T-Lymphocytes pathology, CD8-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes pathology, Cluster Analysis, Cohort Studies, Histocompatibility Antigens Class I metabolism, Histocompatibility Antigens Class II metabolism, Humans, Immunohistochemistry, Lymphocytes, Tumor-Infiltrating pathology, MART-1 Antigen metabolism, Melanoma pathology, Melanoma-Specific Antigens classification, Monophenol Monooxygenase metabolism, Neoplasm Metastasis, T-Lymphocytes pathology, gp100 Melanoma Antigen metabolism, Lymphocytes, Tumor-Infiltrating metabolism, Melanoma metabolism, Melanoma-Specific Antigens metabolism, T-Lymphocytes metabolism
- Abstract
Purpose: Metastasis heterogeneity presents a significant obstacle to the development of targeted cancer therapeutics. In this study, we sought to establish from a large series of human melanoma metastases whether there exists a determined pattern in tumor cellular heterogeneity that may guide the development of future targeted immunotherapies., Experimental Design: From a cohort of 1,514 patients with metastatic melanoma, biopsies were procured over a 17-year period from 3,086 metastatic tumors involving various anatomic sites. To allow specific tumor cell profiling, we used established immunohistochemical methods to perform semiquantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDA), including gp100, MART-1, and tyrosinase. To gain insight into the endogenous host immune response against these tumors, we further characterized tumor cell expression of MHC I and MHC II and, also, the concomitant CD4(+) and CD8(+) T-cell infiltrate., Results: Tumor cell profiling for MDA expression demonstrated an anatomic site-specific pattern of antigen expression that was highest in brain, intermediate in soft tissues/lymph nodes, and lowest in visceral metastases. Hierarchical clustering analysis supported that melanoma metastases have a phylogenetically determined, rather than a stochastic, pattern of antigen expression that varies by anatomic site. Furthermore, tyrosinase expression was more frequently lost in metastatic sites outside of the brain and was uniquely correlated with both endogenous CD8(+) and CD4(+) T-cell infiltrates., Conclusion: Site-specific antigen heterogeneity represents a novel attribute for human melanoma metastases that should be considered in future therapy development and when assessing the responsiveness to antigen-specific immunotherapies., (©2014 American Association for Cancer Research.)
- Published
- 2014
- Full Text
- View/download PDF
16. Adenocarcinoma cells in effusion cytology as a diagnostic pitfall with potential impact on clinical management: a case report with brief review of immunomarkers.
- Author
-
Chowdhuri SR, Fetsch P, Squires J, Kohn E, and Filie AC
- Subjects
- Adenocarcinoma chemistry, Cytodiagnosis, Diagnosis, Differential, Epithelium pathology, Female, Humans, Adenocarcinoma pathology, Adenocarcinoma secondary, Biomarkers, Tumor analysis, Ovarian Neoplasms chemistry, Ovarian Neoplasms pathology, Pleural Effusion, Malignant pathology
- Abstract
Distinguishing metastatic carcinoma cells from reactive mesothelial cells in effusion samples is often challenging based on morphology alone. Metastatic carcinoma cells in fluid samples may mimic reactive mesothelial cells due to overlapping cytological features. We report a case of a pleural effusion in a 51-year-old female patient with a medical history significant for bilateral ovarian tumors and peritoneal implants diagnosed as serous tumor of borderline malignant potential. The effusion was composed almost entirely of adenocarcinoma cells that morphologically mimicked reactive mesothelial cells. The diagnosis of metastatic adenocarcinoma was made after a wide immunostaining panel of antibodies. Recognizing metastatic adenocarcinoma cells in effusion samples can be challenging and an accurate diagnosis may have significant impact on clinical management as demonstrated by this case., (Copyright © 2012 Wiley Periodicals, Inc., a Wiley company.)
- Published
- 2014
- Full Text
- View/download PDF
17. Kba.62 and S100 protein expression in cytologic samples of metastatic malignant melanoma.
- Author
-
Erdag G, Chowdhuri SR, Fetsch P, Erickson D, Hughes MS, and Filie AC
- Subjects
- Biopsy, Fine-Needle, Case-Control Studies, Humans, Melanoma metabolism, Melanoma pathology, Melanoma secondary, Antibodies, Monoclonal, Melanoma diagnosis, Melanoma-Specific Antigens metabolism, S100 Proteins metabolism
- Abstract
The diagnosis of melanoma can be challenging, especially in metastatic lesions, due to the ability of melanoma cells to morphologically mimic carcinoma, sarcoma and even lymphoma cells. Moreover, melanomas can exhibit negative immunostaining for the melanoma markers HMB-45 and MART-1/Melan-A, often used in the diagnosis of this tumor. KBA.62 is a recently described antibody that reacts with benign and malignant melanocytic proliferations. In this study, we report our experience with KBA.62 and S100 protein immunostaining in the diagnosis of metastatic melanoma on fine-needle aspiration and effusion samples. We reviewed 60 cytology samples from 58 patients with metastatic melanoma. Our results showed that KBA.62 stained 75% of the cases and S100 protein 87% of the cases. KBA.62 and S100 protein stained the majority of metastatic melanomas that were negative for HMB-45 and MART-1; KBA.62 stained 73% of the cases and S100 protein 73% of the cases. The majority (85%) of the cases negative for HMB-45 and MART-1 were positive for KBA.62 and/or S100 protein. Additionally, we also observed that KBA.62 staining was positive in the majority of epithelioid and spindle cell type melanoma cells. In conclusion, the performances of KBA.62 and S100 protein were similar and both markers are useful in the diagnosis of metastatic melanoma in cytology material, especially when the tumor cells lack expression of HMB-45 and MART-1., (Copyright © 2012 Wiley Periodicals, Inc., a Wiley company.)
- Published
- 2013
- Full Text
- View/download PDF
18. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
- Author
-
Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, and Hassan R
- Subjects
- Adult, Aged, Antibodies, Monoclonal immunology, Ascites pathology, Female, Flow Cytometry, GPI-Linked Proteins biosynthesis, GPI-Linked Proteins immunology, Humans, Immunohistochemistry, Male, Mesothelin, Mesothelioma pathology, Middle Aged, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms metabolism, Peritoneal Neoplasms pathology, Pleural Effusion, Malignant pathology, Pleural Neoplasms drug therapy, Pleural Neoplasms metabolism, Pleural Neoplasms pathology, Tumor Cells, Cultured, Young Adult, Antibodies, Monoclonal pharmacology, GPI-Linked Proteins deficiency, Mesothelioma drug therapy, Mesothelioma metabolism
- Abstract
Background/aim: To determine if early passage tumor cells obtained from patients with mesothelioma continue to express the tumor differentiation antigen mesothelin and their sensitivity to the anti-mesothelin immunotoxin SS1P., Materials and Methods: Cell cultures were established from ascites or pleural effusion of 6 peritoneal and 3 pleural mesothelioma patients, respectively. These cells were evaluated for mesothelin expression by immunohistochemistry and flow cytometry., Results: Although mesothelin was highly expressed in tumor biopsies of all patients, only 3 out of 9 malignant effusions from these patients when grown in short-term culture showed strong mesothelin positivity by IHC. By flow cytometry, the number of mesothelin sites per cell was variable ranging from 580 to 210,000 sites/cell. Cells with strong mesothelin expression by IHC and increased number of mesothelin sites/cell were sensitive to SS1P., Conclusions: Most mesothelioma tumors loose mesothelin when grown in vitro and the sensitivity of these cells to SS1P is dependent on the number of mesothelin sites/cell.
- Published
- 2012
19. Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells.
- Author
-
Zhang M, Mathur A, Zhang Y, Xi S, Atay S, Hong JA, Datrice N, Upham T, Kemp CD, Ripley RT, Wiegand G, Avital I, Fetsch P, Mani H, Zlott D, Robey R, Bates SE, Li X, Rao M, and Schrump DS
- Subjects
- ATP Binding Cassette Transporter, Subfamily G, Member 2, ATP-Binding Cassette Transporters antagonists & inhibitors, Adenocarcinoma drug therapy, Adenocarcinoma etiology, Adenocarcinoma metabolism, Adenocarcinoma pathology, Animals, Antibiotics, Antineoplastic pharmacology, Esophageal Neoplasms drug therapy, Esophageal Neoplasms etiology, Esophageal Neoplasms pathology, Humans, Lung Neoplasms drug therapy, Lung Neoplasms etiology, Lung Neoplasms pathology, Mice, Mice, Nude, Neoplasm Proteins antagonists & inhibitors, Neoplastic Stem Cells metabolism, Signal Transduction drug effects, Xenograft Model Antitumor Assays, ATP-Binding Cassette Transporters biosynthesis, Esophageal Neoplasms metabolism, Lung Neoplasms metabolism, Neoplasm Proteins biosynthesis, Neoplastic Stem Cells drug effects, Plicamycin pharmacology, Smoke adverse effects, Tobacco Products toxicity
- Abstract
Cigarette smoking at diagnosis or during therapy correlates with poor outcome in patients with lung and esophageal cancers, yet the underlying mechanisms remain unknown. In this study, we observed that exposure of esophageal cancer cells to cigarette smoke condensate (CSC) led to upregulation of the xenobiotic pump ABCG2, which is expressed in cancer stem cells and confers treatment resistance in lung and esophageal carcinomas. Furthermore, CSC increased the side population of lung cancer cells containing cancer stem cells. Upregulation of ABCG2 coincided with increased occupancy of aryl hydrocarbon receptor, Sp1, and Nrf2 within the ABCG2 promoter, and deletion of xenobiotic response elements and/or Sp1 sites markedly attenuated ABCG2 induction. Under conditions potentially achievable in clinical settings, mithramycin diminished basal as well as CSC-mediated increases in AhR, Sp1, and Nrf2 levels within the ABCG2 promoter, markedly downregulated ABCG2, and inhibited proliferation and tumorigenicity of lung and esophageal cancer cells. Microarray analyses revealed that mithramycin targeted multiple stem cell-related pathways in vitro and in vivo. Collectively, our findings provide a potential mechanistic link between smoking status and outcome of patients with lung and esophageal cancers, and support clinical use of mithramycin for repressing ABCG2 and inhibiting stem cell signaling in thoracic malignancies., (©2012 AACR.)
- Published
- 2012
- Full Text
- View/download PDF
20. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
- Author
-
Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, Filie A, Zhang M, Hong JA, Walker RL, Zhu YJ, Ripley RT, Mathur A, Liu F, Yang M, Meltzer PA, Marquez VE, De Rienzo A, Bueno R, and Schrump DS
- Subjects
- Adenosine analogs & derivatives, Adenosine pharmacology, Adult, Aged, Animals, Apoptosis drug effects, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Blotting, Western, Cell Adhesion drug effects, Cell Movement drug effects, Cell Proliferation drug effects, Cells, Cultured, Chromatin Immunoprecipitation, DNA-Binding Proteins antagonists & inhibitors, DNA-Binding Proteins genetics, Enhancer of Zeste Homolog 2 Protein, Female, Gene Expression Profiling, Humans, Immunoenzyme Techniques, Mesothelioma genetics, Mice, Mice, Nude, MicroRNAs genetics, MicroRNAs metabolism, Oligonucleotide Array Sequence Analysis, Pleural Neoplasms genetics, Polycomb Repressive Complex 2, Polycomb-Group Proteins, RNA, Messenger genetics, RNA, Small Interfering genetics, Real-Time Polymerase Chain Reaction, Repressor Proteins antagonists & inhibitors, Repressor Proteins genetics, Transcription Factors antagonists & inhibitors, Transcription Factors genetics, DNA-Binding Proteins metabolism, Mesothelioma drug therapy, Mesothelioma metabolism, Pleural Neoplasms drug therapy, Pleural Neoplasms metabolism, Repressor Proteins metabolism, Transcription Factors metabolism
- Abstract
Purpose: Polycomb group (PcG) proteins are critical epigenetic mediators of stem cell pluripotency, which have been implicated in the pathogenesis of human cancers. This study was undertaken to examine the frequency and clinical relevance of PcG protein expression in malignant pleural mesotheliomas (MPM)., Experimental Design: Microarray, quantitative reverse transcriptase PCR (qRT-PCR), immunoblot, and immunohistochemistry techniques were used to examine PcG protein expression in cultured MPM, mesothelioma specimens, and normal mesothelial cells. Lentiviral short hairpin RNA techniques were used to inhibit EZH2 and EED expression in MPM cells. Proliferation, migration, clonogenicity, and tumorigenicity of MPM cells either exhibiting knockdown of EZH2 or EED, or exposed to 3-deazaneplanocin A (DZNep), and respective controls were assessed by cell count, scratch and soft agar assays, and murine xenograft experiments. Microarray and qRT-PCR techniques were used to examine gene expression profiles mediated by knockdown of EZH2 or EED, or DZNep., Results: EZH2 and EED, which encode components of polycomb repressor complex-2 (PRC-2), were overexpressed in MPM lines relative to normal mesothelial cells. EZH2 was overexpressed in approximately 85% of MPMs compared with normal pleura, correlating with diminished patient survival. Overexpression of EZH2 coincided with decreased levels of miR-101 and miR-26a. Knockdown of EZH2 orEED, or DZNep treatment, decreased global H3K27Me3 levels, and significantly inhibited proliferation, migration, clonogenicity, and tumorigenicity of MPM cells. Common as well as differential gene expression profiles were observed following knockdown of PRC-2 members or DZNep treatment., Conclusions: Pharmacologic inhibition of PRC-2 expression/activity is a novel strategy for mesothelioma therapy., (© 2011 AACR.)
- Published
- 2012
- Full Text
- View/download PDF
21. Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples.
- Author
-
Roy Chowdhuri S, Hanson J, Cheng J, Rodriguez-Canales J, Fetsch P, Balis U, Filie AC, Giaccone G, Emmert-Buck MR, and Hipp JD
- Subjects
- Aspartic Acid Endopeptidases metabolism, Automation, Biomarkers, Tumor metabolism, Hematoxylin, Humans, Immunoenzyme Techniques, Nuclear Proteins metabolism, Thyroid Nuclear Factor 1, Transcription Factors metabolism, Adenocarcinoma diagnosis, Cytodiagnosis, Laser Capture Microdissection, Lung Neoplasms diagnosis, Pleural Effusion, Malignant diagnosis
- Abstract
Objective: In the past decade molecular diagnostics has changed the clinical management of lung adenocarcinoma patients. Molecular diagnostics, however, is largely dependent on the quantity and quality of the tumor DNA that is retrieved from the tissue or cytology samples. Frequently, patients are diagnosed on cytology specimens where the tumor cells are scattered within the cell block, making selecting for tumor enrichment difficult. In the past we have used laser capture microdissection (LCM) to select for pure populations of tumor cells to increase the sensitivity of molecular assays. This study explores several methods for semiautomated computer-guided LCM., Study Design: Hematoxylin and eosin- or TTF-1-immunostained slides from a pleural effusion cell block with metastatic lung adenocarcinoma were used for LCM with either AutoScan or a recently described pattern-matching algorithm, spatially invariant vector quantization (SIVQ), to define morphologic predicates (vectors) to select cells of interest., Results: We retrieved pure populations of tumor cells using both algorithm-guided LCM approaches with slight variations in cellular retrievals. Both methods were semiautomated, requiring minimum technical supervision., Conclusion: In this study we demonstrate the first semiautomated, computer-guided LCM of a cytology specimen using SIVQ and AutoScan, a first step towards the long-term goal of integrating LCM into the clinical cytology-molecular workflow., (Copyright © 2012 S. Karger AG, Basel.)
- Published
- 2012
- Full Text
- View/download PDF
22. The clinical immunohistochemistry laboratory: regulations and troubleshooting guidelines.
- Author
-
Fetsch PA and Abati A
- Subjects
- Laboratories legislation & jurisprudence, Quality Assurance, Health Care legislation & jurisprudence, Quality Assurance, Health Care standards, Quality Control, United States, Immunohistochemistry standards, Laboratories standards
- Abstract
The Clinical Laboratory Improvement Amendments (CLIA) set standards designed to improve the quality of all laboratory testing. In the first portion of this chapter, we discuss the CLIA requirements that apply to most Immunohistochemistry laboratories, and explain topics such as certification, test complexity, patient test management, proficiency testing, personnel, quality control, quality assurance, and compliance. The second portion of this chapter addresses the most common problems encountered in immunohistochemical procedures and the appropriate solutions to correct them.
- Published
- 2010
- Full Text
- View/download PDF
23. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma.
- Author
-
Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, Davis S, Wang C, Cronin JC, Agrawal NS, Lin JC, Westbroek W, Hoogstraten-Miller S, Molinolo AA, Fetsch P, Filie AC, O'Connell MP, Banister CE, Howard JD, Buckhaults P, Weeraratna AT, Brody LC, Rosenberg SA, and Samuels Y
- Subjects
- Chromosomal Instability, Glaucoma congenital, Glioma genetics, Glioma metabolism, Humans, Matrix Metalloproteinase 8 metabolism, Melanoma genetics, Melanoma metabolism, Matrix Metalloproteinase 8 genetics, Melanoma enzymology, Mutation
- Abstract
A mutational analysis of the matrix metalloproteinase (MMP) gene family in human melanoma identified somatic mutations in 23% of melanomas. Five mutations in one of the most commonly mutated genes, MMP8, reduced MMP enzyme activity. Expression of wild-type but not mutant MMP8 in human melanoma cells inhibited growth on soft agar in vitro and tumor formation in vivo, suggesting that wild-type MMP-8 has the ability to inhibit melanoma progression.
- Published
- 2009
- Full Text
- View/download PDF
24. ABCG2: a perspective.
- Author
-
Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, and Bates SE
- Subjects
- ATP Binding Cassette Transporter, Subfamily G, Member 2, ATP-Binding Cassette Transporters genetics, ATP-Binding Cassette Transporters metabolism, Animals, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Biological Transport, Gene Expression drug effects, Humans, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Neoplasms drug therapy, Neoplasms metabolism, Organ Specificity, Substrate Specificity, Tissue Distribution, ATP-Binding Cassette Transporters physiology, Neoplasm Proteins physiology
- Abstract
ABCG2, or breast cancer resistance protein (BCRP), is an ABC transporter that has been the subject of intense study since its discovery a decade ago. With high normal tissue expression in the brain endothelium, gastrointestinal tract, and placenta, ABCG2 is believed to be important in the protection from xenobiotics, regulating oral bioavailability, forming part of the blood-brain barrier, the blood-testis barrier, and the maternal-fetal barrier. Notably, ABCG2 is often expressed in stem cell populations, where it likely plays a role in xenobiotic protection. However, clues to its epigenetic regulation in various cell populations are only beginning to emerge. While ABCG2 overexpression has been demonstrated in cancer cells after in vitro drug treatment, endogenous ABCG2 expression in certain cancers is likely a reflection of the differentiated phenotype of the cell of origin and likely contributes to intrinsic drug resistance. Notably, research into the transporter's role in cancer drug resistance and its development as a therapeutic target in cancer has lagged. Substrates and inhibitors of the transporter have been described, among them chemotherapy drugs, tyrosine kinase inhibitors, antivirals, HMG-CoA reductase inhibitors, carcinogens, and flavonoids. This broad range of substrates complements the efficiency of ABCG2 as a transporter in laboratory studies and suggests that, while there are redundant mechanisms of xenobiotic protection, the protein is important in normal physiology. Indeed, emerging studies in pharmacology and toxicology assessing polymorphic variants in man, in combination with murine knockout models have confirmed its dynamic role. Work in pharmacology may eventually lead us to a greater understanding of the physiologic role of ABCG2.
- Published
- 2009
- Full Text
- View/download PDF
25. The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature.
- Author
-
Fetsch PA and Abati A
- Subjects
- Clone Cells, Epitopes immunology, Female, Hot Temperature, Humans, Immunohistochemistry, Neoplasm Metastasis, Antibodies, Neoplasm immunology, Breast Neoplasms immunology, Breast Neoplasms pathology, Receptor, ErbB-2 immunology
- Abstract
The standardization and use of heat-induced epitope retrieval (HIER) is particularly important with immunohistochemical markers that direct the course of cancer treatment, such as Herceptin therapy. Increasingly, many laboratories are performing immunohistochemical analysis using various antibodies and methodologies for HER2/neu. We attempted to determine the effects of antibody clone and pretreatment methods on the interpretation of HER-2/neu staining in cytologic samples. Cell block sections from 54 cases of metastatic breast cancer (24 FNAs, 30 effusions) were analyzed for HER2 expression using antibodies to CB-11, TAB250, and A0485. Antibodies were analyzed with and without HIER. One pathologist using the FDA-approved scoring system for the HercepTest reviewed all slides in a blinded fashion. Five of fifty-four cases (9%) using CB-11 showed a significant increase in HER2 immunoreactivity using HIER (i.e. from 0/1+ to 2-3+). However, in twenty-nine of fifty-four cases (54%), the cytoplasmic background was significantly higher after HIER. With the A0485 antibody, two of fifty four cases (4%) showed a significant increase in immunoreactivity using HIER, while seventeen of fifty-four cases (31%) exhibited only more pronounced cytoplasmic staining. HIER pretreatment did not increase HER2 staining in any TAB250 stained sample, rather four of fifty-four cases (7%) showed a significant decrease in staining with HIER. We conclude that HIER may enhance membrane staining with the CB-11 and A0485 antibodies, but also increases cytoplasmic background. Loss of antigenicity is seen when HIER is used with TAB250.
- Published
- 2007
- Full Text
- View/download PDF
26. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.
- Author
-
Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, Fetsch P, Filie A, Walters SA, Astry C, Aricó E, Zhao Y, Selleri S, Wang E, and Marincola FM
- Subjects
- Aminoquinolines pharmacology, Antineoplastic Agents pharmacology, CD56 Antigen immunology, CD8 Antigens immunology, Carcinoma, Basal Cell drug therapy, Carcinoma, Basal Cell pathology, Genes, Neoplasm, Humans, Imiquimod, Interferon-alpha genetics, Interferon-alpha metabolism, Interferon-gamma genetics, Interferon-gamma metabolism, Placebos, Polymerase Chain Reaction, RNA, Messenger genetics, RNA, Messenger metabolism, Aminoquinolines therapeutic use, Antineoplastic Agents therapeutic use, Carcinoma, Basal Cell genetics, Carcinoma, Basal Cell immunology, Gene Expression Profiling, Gene Expression Regulation, Neoplastic drug effects
- Abstract
Background: Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological events preceding acute tissue and/or tumor rejection., Results: We report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected to local application of imiquimod (n = 22) or vehicle cream (n = 14) in a blinded, randomized protocol. Four treatments were assessed (q12 applications for 2 or 4 days, or q24 hours for 4 or 8 days). RNA was amplified and hybridized to 17.5 K cDNA arrays. All treatment schedules similarly affected the transcriptional profile of BCC; however, the q12 x 4 days regimen, associated with highest effectiveness, induced the most changes, with 637 genes unequivocally stimulated by imiquimod. A minority of transcripts (98 genes) confirmed previous reports of interferon-alpha involvement. The remaining 539 genes portrayed additional immunological functions predominantly involving the activation of cellular innate and adaptive immune-effector mechanisms. Importantly, these effector signatures recapitulate previous observations of tissue rejection in the context of cancer immunotherapy, acute allograft rejection and autoimmunity., Conclusion: This study, based on a powerful and reproducible model of cancer eradication by innate immune mechanisms, provides the first insights in humans into the early transcriptional events associated with immune rejection. This model is likely representative of constant immunological pathways through which innate and adaptive immune responses combine to induce tissue destruction.
- Published
- 2007
- Full Text
- View/download PDF
27. Diagnostic effects of prolonged storage on fresh effusion samples.
- Author
-
Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, and Abati A
- Subjects
- Adult, Ascitic Fluid chemistry, Biomarkers, Tumor, DNA, Neoplasm analysis, Female, Humans, Male, Middle Aged, Pleural Effusion, Malignant genetics, Polymerase Chain Reaction, Time Factors, Artifacts, Ascitic Fluid pathology, Cytodiagnosis methods, Neoplasms diagnosis, Pleural Effusion, Malignant diagnosis, Specimen Handling methods
- Abstract
The effects on morphology and diagnostic interpretation of delayed processing of refrigerated effusion samples have not been well documented. The potential for cellular degeneration has led many laboratories to reflexively fix samples rather than submit fresh/refrigerated samples for cytologic examination. We sought to determine if effusion specimens are suitable for morphologic, immunocytochemical, and DNA-based molecular studies after prolonged periods of refrigerated storage time. Ten fresh effusion specimens were refrigerated at 4 degrees C; aliquots were processed at specific points in time (days 0, 3, 5, 7, 10, 14). Specimens evaluated included four pleural (3 benign, 1 breast adenocarcinoma) and six peritoneal (2 ovarian adenocarcinomas, 1 malignant melanoma, 2 mesotheliomas, 1 atypical mesothelial) effusions. The morphology of the cytologic preparations from the 10 effusions was preserved and interpretable after 14 days of storage at 4 degrees C. The immunocytochemical profile of the samples (AE1/AE3, EMA, calretinin, and LCA) was consistent from day 0 to day 14. Amplifiable DNA was present in all samples tested on day 14. We conclude that cytopathologic interpretation of effusion samples remains reliable with refrigeration at 4 degrees C even if processing is delayed.
- Published
- 2007
- Full Text
- View/download PDF
28. The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2.
- Author
-
Robey RW, Fetsch PA, Polgar O, Dean M, and Bates SE
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP Binding Cassette Transporter, Subfamily G, Member 2, ATP-Binding Cassette Transporters chemistry, Amino Acid Sequence, Animals, Cattle, Cell Line, Chlorophyll adverse effects, Chlorophyll metabolism, Gene Expression Regulation, Humans, Liver cytology, Liver metabolism, Molecular Sequence Data, Neoplasm Proteins chemistry, Pancreas cytology, Pancreas metabolism, Sheep, Swine, ATP-Binding Cassette Transporters metabolism, Chlorophyll analogs & derivatives, Neoplasm Proteins metabolism, Organic Anion Transporters metabolism
- Abstract
Hepatogenous photosensitization occurs in livestock following damage to the liver or biliary apparatus that results in impaired excretion of phytoporphyrin (phylloerythrin), a photosensitizer. Based on earlier observations that porphyrin-based photosensitizers are substrates of the ATP-binding cassette transporter ABCG2, we examined the ability of the hepatic transporters ABCB1 (P-glycoprotein) and ABCG2 to transport phytoporphyrin. Transport of phytoporphyrin was blocked by the ABCG2-specific inhibitor fumitremorgin C (FTC) in human embryonic kidney cells transfected with full length human ABCG2, while no transport by cells transfected with human ABCB1 was noted. FTC-inhibited transport of phytoporphyrin was also demonstrated in ABCG2-expressing LLC-PK1 pig kidney cells, consistent with the idea that the pig orthologue, like human ABCG2, transports the photosensitizer. ABCG2 expression was confirmed by immunohistochemistry in the hepatocytes of cow, pig and sheep livers. We conclude that phytoporphyrin is a substrate for ABCG2 and that the transporter is likely responsible for its biliary excretion.
- Published
- 2006
- Full Text
- View/download PDF
29. There may be "madness in the methods," but the devil is in the details.
- Author
-
Fetsch PA, Simsir A, and Abati A
- Subjects
- Humans, Immunohistochemistry standards, Polymerase Chain Reaction standards, Immunohistochemistry methods, Liver pathology, Polymerase Chain Reaction methods, Research Design standards
- Published
- 2006
- Full Text
- View/download PDF
30. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
- Author
-
Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, and Topalian SL
- Subjects
- Combined Modality Therapy, DNA, Recombinant genetics, Genetic Vectors genetics, Humans, Immunization Schedule, Immunoglobulin G blood, Interferon-gamma genetics, Interferon-gamma metabolism, Interleukin-2 administration & dosage, Melanoma immunology, Melanoma pathology, Monophenol Monooxygenase genetics, Monophenol Monooxygenase immunology, Monophenol Monooxygenase metabolism, Neoplasm Metastasis, Poxviridae genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Reverse Transcriptase Polymerase Chain Reaction, T-Lymphocytes drug effects, T-Lymphocytes immunology, T-Lymphocytes metabolism, Treatment Outcome, Cancer Vaccines immunology, DNA, Recombinant immunology, Immunization, Secondary methods, Interleukin-2 therapeutic use, Melanoma therapy, Vaccination methods
- Abstract
Purpose: Two clinical trials were conducted to evaluate the clinical efficacy and immunologic impact of vaccination against the tyrosinase protein plus systemic interleukin 2 (IL-2) administration in patients with advanced metastatic melanoma., Experimental Design: Full-length tyrosinase was employed as an immunogen to induce diverse immunologic responses against a commonly expressed melanoma antigen. Heterologous prime/boost vaccination with recombinant vaccinia and fowlpox vectors encoding tyrosinase was first explored in a randomized three-arm phase II trial, in which vaccines were administered alone or concurrently with low-dose or high-dose IL-2. In a subsequent single cohort phase II trial, all patients received the same vaccines and high-dose IL-2 sequentially rather than concurrently., Results: Among a total of 64 patients treated on these trials, 8 objective partial responses (12.5%) were observed, all in patients receiving high-dose IL-2. Additional patients showed evidence of lesional regression (mixed tumor response) or overall regression that did not achieve partial response status (minor response). In vitro evidence of enhanced immunity against tyrosinase following protocol treatments was documented in 3 of 49 (6%) patients tested serologically, 3 of 23 (13%) patients tested for T-cell recognition of individual tyrosinase peptides, and 4 of 16 (25%) patients tested for T-cell recognition of full-length tyrosinase protein with real-time reverse transcription-PCR techniques., Conclusions: Whereas prime/boost immunization with recombinant vaccinia and fowlpox viruses enhanced antityrosinase immunity in some patients with metastatic melanoma, it was ineffective alone in mediating clinical benefit, and in combination with IL-2 did not mediate clinical benefit significantly different from that expected from treatment with IL-2 alone.
- Published
- 2006
- Full Text
- View/download PDF
31. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.
- Author
-
Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, and Bates SE
- Subjects
- ATP Binding Cassette Transporter, Subfamily G, Member 2, ATP-Binding Cassette Transporters genetics, Blotting, Northern, Humans, Immunoenzyme Techniques, Neoplasm Proteins genetics, Paraffin Embedding, RNA, Messenger genetics, RNA, Messenger metabolism, Tissue Distribution, ATP-Binding Cassette Transporters metabolism, Drug Resistance, Multiple, Neoplasm Proteins metabolism
- Abstract
Reduced drug accumulation due to overexpression of individual members of the ATP binding cassette (ABC) superfamily of membrane transporters has been investigated as a cause of multidrug resistance and treatment failure in oncology. This study was designed to develop an immunohistochemical assay to determine the expression and localization of the 72kDa ABC half-transporter ABCG2 in normal tissues. Formalin-fixed, paraffin embedded archival tissue from 31 distinct normal tissues with an average of eight separate tissue samples of each were immunostained with rabbit-anti-ABCG2 antibody 405 using a modified avidin-biotin procedure. As a negative control, each sample was also stained with antibody pre-adsorbed with peptide to assess background staining. As a means of verification, selected tissues were also stained with the commercially available monoclonal antibody 5D3. ABCG2 positivity was consistently found in alveolar pneumocytes, sebaceous glands, transitional epithelium of bladder, interstitial cells of testes, prostate epithelium, endocervical cells of uterus, squamous epithelium of cervix, small and large intestinal mucosa/epithelial cells, islet and acinar cells of pancreas, zona reticularis layer of adrenal gland, kidney cortical tubules and hepatocytes. Placental syncytiotrophoblasts showed both cytoplasmic and surface staining. Our results support a hypothesis concluding that ABCG2 plays a role in the protection of organs from cytotoxins. However, many of the cell types expressing ABCG2 have a significant secretory function. These data suggest a dual function for ABCG2 in some tissues: the excretion of toxins and xenobiotics including anti-cancer agents and a potential, as-yet undefined role in the secretion of endogenous substrates.
- Published
- 2006
- Full Text
- View/download PDF
32. Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications.
- Author
-
Fetsch PA, Simone NL, Bryant-Greenwood PK, Marincola FM, Filie AC, Petricoin EF, Liotta LA, and Abati A
- Subjects
- Humans, Peptide Mapping, Tissue Preservation, Carcinoma, Renal Cell chemistry, Carcinoma, Renal Cell pathology, Melanoma chemistry, Melanoma pathology, Proteome analysis, Sarcoma chemistry, Sarcoma pathology, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
- Abstract
Proteomic studies of cells via surface-enhanced laser desorption/ionization spectrometry (SELDI) analysis have enabled rapid, reproducible protein profiling directly from crude samples. We applied this technique to archival cytology material to determine whether distinct, reproducible protein fingerprints could be identifiedfor potential diagnostic purposes in blinded specimens. Rapid Romanowsky-stained cytocentrifuged specimens from fine-needle aspirates of metastatic malignant melanoma (with both known cutaneous primary and unknown primary sites), clear cell sarcoma, and renal cell carcinoma and reactive effusions were examined using the SELDI technology. A unique characteristic fingerprint was identified for each disease entity. Fifteen "blinded" unknown samples then were analyzed. When the protein profilefingerprints were plotted against the known fingerprints for the aforementioned diagnoses, the appropriate match or diagnosis was obtained in 13 (87%) of 15 cases. These preliminary findings suggest a substantial potential for SELDI applications to specific pathologic diagnoses.
- Published
- 2002
- Full Text
- View/download PDF
33. Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.
- Author
-
Litman T, Jensen U, Hansen A, Covitz KM, Zhan Z, Fetsch P, Abati A, Hansen PR, Horn T, Skovsgaard T, and Bates SE
- Subjects
- ATP Binding Cassette Transporter, Subfamily G, Member 2, ATP-Binding Cassette Transporters analysis, ATP-Binding Cassette Transporters immunology, Amino Acid Sequence, Antibodies immunology, Cell Line, Drug Resistance, Multiple, Epitopes immunology, Fluorescent Antibody Technique, Humans, Immunoblotting, Microscopy, Confocal, Microscopy, Immunoelectron, Molecular Sequence Data, Neoplasm Proteins analysis, Neoplasm Proteins immunology, Peptides chemical synthesis, Peptides immunology, ATP-Binding Cassette Transporters chemistry, Antibodies chemistry, Mitoxantrone chemistry, Neoplasm Proteins chemistry
- Abstract
Recent studies have characterized the ABC half-transporter associated with mitoxantrone resistance in human cancer cell lines. Encoded by the ABCG2 gene, overexpression confers resistance to camptothecins, as well as to mitoxantrone. We developed four polyclonal antibodies against peptides corresponding to four different epitopes on the mitoxantrone resistance-associated protein, ABCG2. Three epitopes localized on the cytoplasmic region of ABCG2 gave rise to high-affinity antibodies, which were demonstrated to be specific for ABCG2. Western blot analysis of cells with high levels of ABCG2 showed a single major band of the expected 72-kDa molecular size of ABCG2 under denaturing conditions. Immunoblot analysis performed under non-reducing conditions and after treatment with cross-linking reagents demonstrated a molecular weight shift from 72 kDa to several bands of 180 kDa and higher molecular weight, suggesting detection of dimerization products of ABCG2. Evidence of N-linked glycosylation was also obtained using tunicamycin and N-glycosidase F. Finally, both by light, fluorescence and electron microscopic immunohistochemical staining, we demonstrate cytoplasmic and predominantly plasma membrane localization of ABCG2 in cell lines with high levels of expression. Plasma membrane staining was observed on the surface of the chorionic villi in placenta. These results support the hypothesis that ABCG2 is an ABC half-transporter that forms dimers in the plasma membrane, functioning as an ATP-dependent outward pump for substrate transport.
- Published
- 2002
- Full Text
- View/download PDF
34. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry.
- Author
-
Fetsch PA, Simsir A, Brosky K, and Abati A
- Subjects
- Adenocarcinoma chemistry, Adenocarcinoma secondary, Antigens, Neoplasm analysis, Ascitic Fluid pathology, Biomarkers, Tumor analysis, Female, Humans, Neoplasms chemistry, Neoplasms pathology, Pleural Effusion, Malignant pathology, Reproducibility of Results, Ascitic Fluid chemistry, Cytodiagnosis methods, Immunohistochemistry methods, Pleural Effusion, Malignant chemistry
- Abstract
Discrepant results in effusion immunocytochemistry are often the result of specimen processing. Smears, cytospins, cell blocks, and monolayer preparations have all been used in various published studies; thus, there is no consistency in the immunostaining process for cytology to compare with the surgical pathology "gold standard" results. We sought to evaluate optimal specimen preparation for the immunostaining of effusion samples. Fourteen reactive and 15 malignant effusion samples (various epithelial/mesothelial neoplasms) were each prepared in three forms: air-dried cytospins (postfixed in ethanol), formalin-fixed, paraffin-embedded cell blocks, and liquid-based thin-layer (ThinPrep, CYTYC, Boxborough, MA) processing. All slides were immunostained with antibodies commonly used in effusion cytology: HBME-1, calretinin, E-cadherin, BerEP4, B72.3, LeuM1, and CA19-9. Cytospin and ThinPrep samples performed in a similar manner: high background staining was encountered in 66% of cases, most evident in three-dimensional clusters of cells. In addition, membrane staining patterns were difficult to interpret. Cell blocks provided the best milieu for morphologic interpretation, with less background staining (only 17% of cases) and results that most closely approximated those reported in the surgical pathology literature. The cost per test for cell block immunocytochemistry was also the most economical for our laboratory.
- Published
- 2002
- Full Text
- View/download PDF
35. Melanoma metastatic to the breast: utility of fine needle aspiration and immunohistochemistry.
- Author
-
Filie AC, Simsir A, Fetsch P, and Abati A
- Subjects
- Adult, Aged, Antigens, Neoplasm metabolism, Biomarkers, Biopsy, Needle, Breast Neoplasms metabolism, Female, Humans, Immunohistochemistry, Keratins metabolism, MART-1 Antigen, Melanoma metabolism, Melanoma-Specific Antigens, Middle Aged, Monophenol Monooxygenase metabolism, Neoplasm Proteins metabolism, Skin Neoplasms pathology, Breast Neoplasms pathology, Breast Neoplasms secondary, Melanoma pathology, Melanoma secondary
- Abstract
Objective: To describe the morphologic spectrum of metastatic malignant melanoma (MM) cells involving the breast and to explore the diagnostic utility of HMB45, Mart-1, Melan-A and T311 (antityrosinase) antibodies in fine needle aspiration material of MM metastatic to the breast., Study Design: Cytologic material from 21 cases (18 women) was reviewed for cytomorphology (epithelioid, spindled, mixed) and immunocytochemical staining attributes for Mart-1, HMB45, T311, Melan-A and cytokeratin based on tissue availability., Results: Seventeen cases (81%) demonstrated epithelioid cell morphology, with 14% exhibiting mixed and 5% spindled morphologies. All 21 cases (100%) were immunoreactive with Mart-1 antibody, with 81% (17/21) immunoreactive for HMB45. In 38% of cases there was a similar percentage of cells immunoreactive for Mart-1 and HMB45, while 48% showed a higher percentage of cells immunoreactive for MART-1 than HMB45. Immunoreactivity with T311 was seen in 8 of 11 cases tested (73%). All six cases tested (100%) were immunoreactive with Melan-A. Staining for cytokeratin was negative in all eight cases tested., Conclusion: Because the majority of MM metastatic to the breast shows epithelioid cell morphology, it may mimic primary breast carcinoma. Mart-1 should be part of the immunocytochemical panel utilized to confirm the diagnosis of MM metastatic to the breast.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.